Navigation Links
RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
Date:12/29/2012

Buffalo, NY (PRWEB) December 28, 2012

Researchers from Roswell Park Cancer Institute (RPCI) have published findings from a preclinical study assessing the effectiveness of a small-molecule inhibitor, CFAK-Y15, in treating some brain cancers. The paper, published in Molecular Cancer Therapeutics, demonstrates for the first time that inhibiting the protein focal adhesion kinase (FAK) with CFAK-Y15 is an effective approach to controlling growth of glioblastoma tumors, especially in combination with the standard chemotherapy agent temozolomide (Temodar).

FAK is overexpressed, or produced in excessive amounts, in tumor cells, and has been shown to play a key role in survival of cancer cells. In this study, a team led by Vita M. Golubovskaya, PhD, an Associate Professor of Oncology in the Department of Surgical Oncology, found that animal models treated with CFAK-Y15 demonstrated significantly prolonged survival compared to the control group. CFAK-Y15 provides FAK kinase-specific inhibition by upstream targeting of autophosphorylation sites on the FAK protein. It belongs to a class of ‘two for one’ compounds that also inhibit the oncoprotein Src by inhibiting its autophosphorylation.

“We found that CFAK-Y15 significantly decreased the viability of the glioblastoma cells, and in many cases appeared to cause tumor shrinkage — especially when CFAK-Y15 was given in combination with temozolomide,” noted Dr. Golubovskaya, the paper’s first author. “These compounds target FAK signaling, which is critical for cancer cell and cancer stem cell survival, especially in invasive and metastatic cancers.”

“We’re eager to see this research move to the clinical phase because of the great need for more effective treatments for glioblastoma,” noted senior author William G. Cance, MD, FACS, Surgeon-in-Chief and Chair of the Department of Surgical Oncology. “The potential impact is great because glioblastomas are such an aggressive tumor, and because we know they produce FAK in especially high quantities.”

The authors also included researchers from the University of California at San Diego and faculty from the Department of Pathology at RPCI. CFAK-Y15 is being developed by CureFAKtor Pharmaceuticals LLC (http://www.curefaktor.com). Drs. Cance and Golubovskaya, both of whom also serve on the management team of CureFAKtor, were part of the team that first identified CFAK-Y15, in research published in the Journal of Medicinal Chemistry in 2008.

The new abstract and paper, “Pharmacological blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide,” can be accessed online at http://mct.aacrjournals.org/content/early/2012/12/12/1535-7163.MCT-12-0701.

This work was supported by Susan Komen for the Cure Foundation grant BCTR0707148 and three National Cancer Institute (NCI) grants: R01CA065910, R01HL073396, and the NCI’s Cancer Center Support Grant for Roswell Park Cancer Institute (P30CA016056).

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI’s website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci(at)roswellpark(dot)org.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10265721.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Nature Materials study: Boosting heat transfer with nanoglue
2. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
3. Nature Materials study: Graphene invisible to water
4. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
5. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
6. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
7. Kinase Inhibitors: Global Markets -- Focus on the U.S.
8. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
9. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
10. Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
11. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... PBI-Gordon Corporation is pleased to announce Dave Loecke has accepted the position ... PBI-Gordon, Dave has served in a wide variety of roles. His most recent position ... of many of PBI-Gordon’s most successful products. , “Dave has been essential to the ...
(Date:5/26/2016)... New Jersey and READING, ... Indegene ( http://www.indegene.com ), a leading ... to life science, pharmaceutical and healthcare organisations and ... of innovative scientific support throughout the product lifecycle, ... with the launch of IntraScience.      ...
(Date:5/26/2016)... ... May 26, 2016 , ... FireflySci ... used in leading laboratories all over the globe. Their cute firefly logo has ... manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards that never require recalibration. ...
(Date:5/25/2016)... Md. (PRWEB) , ... May 25, 2016 , ... ... request for information (RFI) issued by the Office of the National Coordinator for ... patient experience, and determines if clinically relevant data were available when and where ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):